Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -184.27% is 134% below its 5-year average of -78.75%, near the low end of its 5-year range (-185.04%–-26.58%).
As of the fiscal period ended Tuesday, June 30, 2026. 66.92% below its 12-month average of -110.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -184.27%.
RETURN ON EQUITY (ROE)
-184.27%
RETURN ON EQUITY (ROE) AVG TTM
-110.39%
RETURN ON EQUITY (ROE) AVG 3Y
-87.65%
RETURN ON EQUITY (ROE) AVG 5Y
-78.75%
RETURN ON EQUITY (ROE) AVG 10Y
-148.26%
RETURN ON EQUITY (ROE) AVG 15Y
-106.56%
RETURN ON EQUITY (ROE) AVG 20Y
-108.42%
CURRENT VS TTM AVG
-66.92%
CURRENT VS 3Y AVG
-110.23%
CURRENT VS 5Y AVG
-134.00%
CURRENT VS 10Y AVG
-24.29%
CURRENT VS 15Y AVG
-72.92%
CURRENT VS 20Y AVG
-69.96%
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 623 covered companies
CURRENT VS SECTOR MEDIAN
-358.38%
vs the sector median at left
EyePoint Pharmaceuticals, Inc.
Market Cap
$268.71M
Return on Equity (ROE)
-184.27%
TTM Avg
-110.39%
3Y Avg
-87.65%
5Y Avg
-78.75%
Market Cap
$268.17M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$267.91M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$266.05M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$263.05M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$274.62M
Return on Equity (ROE)
-4.68%
TTM Avg
-68.17%
3Y Avg
-57.88%
5Y Avg
-49.64%
Market Cap
$261.79M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$278.55M
Return on Equity (ROE)
-82.12%
TTM Avg
-62.12%
3Y Avg
-56.53%
5Y Avg
-50.41%
Market Cap
$257.96M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EyePoint Pharmaceuticals, Inc. (EYPT) | $268.71M | -184.27% | -110.39% | -87.65% | -78.75% |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | -15.46% | -12.46% | -4.29% | -4.49% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.91M | -38.33% | -61.68% | -393.03% | -278.88% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.05M | -39.55% | -28.46% | -79.02% | -63.95% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.05M | -37.12% | -62.34% | -32.67% | 8.91% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | -4.68% | -68.17% | -57.88% | -49.64% |
| Palisade Bio, Inc. (PALI)vs › | $261.79M | -26.24% | -102.84% | -107.17% | -107.44% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.55M | -82.12% | -62.12% | -56.53% | -50.41% |
| AC Immune S.A. (ACIU)vs › | $257.96M | -124.67% | -101.06% | -69.44% | -56.33% |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -21.41% | -11.72% | -50.56% | -98.46% |
ROE
-184.3%
ROA
-134.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -184.27% |
| 2026-03-31 | -117.84% |
| 2025-12-31 | -75.78% |
| 2025-09-30 | -102.78% |
| 2025-06-30 | -71.29% |
| 2025-03-31 | -49.19% |
| 2024-12-31 | -38.89% |
| 2024-09-30 | -47.35% |
| 2024-06-30 | -38.03% |
| 2024-03-31 | -31.57% |
| 2023-12-31 | -26.58% |
| 2023-09-30 | -170.84% |
| 2023-06-30 | -185.04% |
| 2023-03-31 | -130.68% |
| 2022-12-31 | -106.11% |
| 2022-09-30 | -57.38% |
| 2022-06-30 | -50.55% |
| 2022-03-31 | -40.23% |
| 2021-12-31 | -31.68% |
| 2021-09-30 | -58.71% |
| 2021-06-30 | -38.89% |
| 2021-03-31 | -38.46% |
| 2020-12-31 | -244.83% |
| 2020-09-30 | -531.14% |
| 2020-03-31 | -307.93% |
| 2019-12-31 | -681.79% |
| 2019-09-30 | -363.77% |
| 2019-06-30 | -267.48% |
| 2019-03-31 | -494.97% |
| 2018-12-31 | -228.86% |
| 2018-09-30 | -168.36% |
| 2018-06-30 | -454.96% |
| 2018-03-31 | -303.23% |
| 2017-12-31 | -232.42% |
| 2017-09-30 | -192.27% |
| 2017-06-30 | -138.61% |
| 2017-03-31 | -149.93% |
| 2016-12-31 | -126.39% |
| 2016-09-30 | -164.56% |
| 2016-06-30 | -103.19% |
| 2016-03-31 | -76.47% |
| 2015-12-31 | -140.48% |
| 2015-09-30 | -101.75% |
| 2015-06-30 | 27.16% |
| 2015-03-31 | 27.03% |
| 2014-12-31 | 32.03% |
| 2014-09-30 | 30.44% |
| 2014-06-30 | -89.49% |
| 2014-03-31 | -72.69% |
| 2013-12-31 | -110.66% |
| 2013-09-30 | -91.56% |
| 2013-06-30 | -154.55% |
| 2013-03-31 | -90.87% |
| 2012-12-31 | -73.19% |
| 2012-09-30 | -154.42% |
| 2012-06-30 | -182.13% |
| 2012-03-31 | -146.02% |
| 2011-12-31 | -127.65% |
| 2011-09-30 | -22.56% |
| 2011-06-30 | -23.05% |
| 2011-03-31 | 12.39% |
| 2010-09-30 | 23.26% |
| 2010-06-30 | 26.49% |
| 2010-03-31 | -24.79% |
| 2009-12-31 | -12.39% |
| 2009-09-30 | -16.83% |
| 2009-06-30 | -10.67% |
| 2009-03-31 | -310.88% |
| 2008-12-31 | -323.17% |
| 2008-09-30 | -275.75% |
| 2008-06-30 | -251.58% |
| 2008-03-31 | -28.63% |
| 2007-12-31 | -30.35% |
| 2007-09-30 | -133.67% |
| 2007-06-30 | -116.48% |
| 2005-06-30 | -18.17% |
| 2004-06-30 | -9.66% |
| 2003-06-30 | -43.59% |
